Crescent BiopharmaFRA:C68 18 EPS without NRI is €-9.39 as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,168 Biotechnology companies, Crescent Biopharma ranks worse than 85616.35% on this metric.
Crescent Biopharma's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.61.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-9.39.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Crescent Biopharma's EPS without NRI or its related term are showing as below:
FRA:C68's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.4 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Crescent Biopharma's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.61.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-9.39.
Crescent Biopharma (FRA:C68) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Crescent Biopharma EPS without NRI Related Terms
Crescent Biopharma EPS without NRI Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:C68 vs KYTX, ZURA, ARVN: EPS without NRI Comparison
For the Biotechnology subindustry, Crescent Biopharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma (FRA:C68) has a EPS without NRI of €-9.39 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #999999 out of 1168 companies in the Biotechnology industry.
Is Crescent Biopharma's EPS without NRI too high?
Crescent Biopharma's current EPS without NRI is €-9.39. Based on the distribution chart, Crescent Biopharma ranks #999999 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's EPS without NRI compare to KYTX and ZURA?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #999999 out of 1168 companies for EPS without NRI. This places Crescent Biopharma in the lower half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Crescent Biopharma and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescent Biopharma's current EPS without NRI is €-9.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current EPS without NRI of €-9.39. The current EPS without NRI is €-9.39. Crescent Biopharma's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current EPS without NRI is €-9.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score
Get the complete analysis for FRA:C68
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C68 has been successfully added to your 